Suppression of Antitumor Immunity by Stromal Cells Expressing Fibroblast Activation Protein-α

被引:909
作者
Kraman, Matthew [1 ]
Bambrough, Paul J. [1 ]
Arnold, James N. [1 ]
Roberts, Edward W. [1 ]
Magiera, Lukasz [1 ]
Jones, James O. [1 ]
Gopinathan, Aarthi [2 ,3 ]
Tuveson, David A. [2 ]
Fearon, Douglas T. [1 ]
机构
[1] Univ Cambridge, MRC Ctr, Dept Med, Wellcome Trust Immunol Unit, Cambridge CB2 2QH, England
[2] Canc Res UK, Cambridge Res Inst, Li Ka Shing Ctr, Cambridge CB2 0RE, England
[3] Univ Penn, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA
基金
英国惠康基金;
关键词
IFN-GAMMA; T-CELLS; TUMOR PROGRESSION; HUMAN-MELANOMA; BONE-MARROW; CANCER; INHIBITION; GROWTH; DIFFERENTIATION; IMMUNOGENICITY;
D O I
10.1126/science.1195300
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
The stromal microenvironment of tumors, which is a mixture of hematopoietic and mesenchymal cells, suppresses immune control of tumor growth. A stromal cell type that was first identified in human cancers expresses fibroblast activation protein-alpha (FAP). We created a transgenic mouse in which FAP-expressing cells can be ablated. Depletion of FAP-expressing cells, which made up only 2% of all tumor cells in established Lewis lung carcinomas, caused rapid hypoxic necrosis of both cancer and stromal cells in immunogenic tumors by a process involving interferon-gamma and tumor necrosis factor-alpha. Depleting FAP-expressing cells in a subcutaneous model of pancreatic ductal adenocarcinoma also permitted immunological control of growth. Therefore, FAP-expressing cells are a nonredundant, immune-suppressive component of the tumor microenvironment.
引用
收藏
页码:827 / 830
页数:4
相关论文
共 30 条
[1]   Fibroblast activation protein α identifies mesenchymal stromal cells from human bone marrow [J].
Bae, Sohyun ;
Park, Chae Woon ;
Son, Hye Kyung ;
Ju, Hye Kyung ;
Paik, Donggi ;
Jeon, Choon-Ju ;
Koh, Gou Young ;
Kim, Jaeseob ;
Kim, Hoeon .
BRITISH JOURNAL OF HAEMATOLOGY, 2008, 142 (05) :827-830
[2]   Fibroblast activation protein is expressed by rheumatoid myofibroblast-like synoviocytes [J].
Bauer, Stefan ;
Jendro, Michael C. ;
Wadle, Andreas ;
Kleber, Sascha ;
Stenner, Frank ;
Dinser, Robert ;
Reich, Anja ;
Faccin, Erica ;
Goedde, Stefan ;
Dinges, Harald ;
Mueller-Ladner, Ulf ;
Renner, Christoph .
ARTHRITIS RESEARCH & THERAPY, 2006, 8 (06)
[3]  
BERENDT MJ, 1980, J EXP MED, V151, P69, DOI 10.1084/jem.151.1.69
[4]   IFN-γ- and TNF-dependent bystander eradication of antigen-loss variants in established mouse cancers [J].
Bin Zhang ;
Karrison, Theodore ;
Rowley, Donald A. ;
Schreiber, Hans .
JOURNAL OF CLINICAL INVESTIGATION, 2008, 118 (04) :1398-1404
[5]   CIRCULATING FIBROCYTES DEFINE A NEW LEUKOCYTE SUBPOPULATION THAT MEDIATES TISSUE-REPAIR [J].
BUCALA, R ;
SPIEGEL, LA ;
CHESNEY, J ;
HOGAN, M ;
CERAMI, A .
MOLECULAR MEDICINE, 1994, 1 (01) :71-81
[6]  
Dolznig Helmut, 2005, Cancer Immun, V5, P10
[7]  
DOUKAS J, 1990, J IMMUNOL, V145, P1727
[8]   Interferons, immunity and cancer immunoediting [J].
Dunn, Gavin P. ;
Koebel, Catherine M. ;
Schreiber, Robert D. .
NATURE REVIEWS IMMUNOLOGY, 2006, 6 (11) :836-848
[9]  
DVORAK HF, 1986, NEW ENGL J MED, V315, P1650
[10]   CELL-SURFACE GLYCOPROTEIN OF REACTIVE STROMAL FIBROBLASTS AS A POTENTIAL ANTIBODY TARGET IN HUMAN EPITHELIAL CANCERS [J].
GARINCHESA, P ;
OLD, LJ ;
RETTIG, WJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1990, 87 (18) :7235-7239